Objective: To conduct a survey in seven European cancer genetics centres to compare service provision, organisation and practices for familial breast and colon cancer consultations and testing. Information was obtained on aspects of services both nationally and locally. Methods: A detailed survey questionnaire was adapted collaboratively to obtain the required information. Initial survey data were collected within each centre and interim results were discussed at two European Workshops. Where differences in practice existed, details were clarified to ensure accuracy and adequacy of information. Participating centres were Haifa (Israel), Hannover (Germany), Leiden (The Netherlands), Leuven (Belgium), Manchester (UK), Marseille (France) and Milan (Italy), representing countries with populations ranging from 6.5 to 80 million. Results: The European countries diverged in regard to the number of cancer genetics centres nationally (from 8 in Belgium to 37 in France), and the average population served by each centre (from 0.59 million in Israel to 3.32 million in Italy). All centres offered free care at the point of access, but referral to specialist care varied according to national health care provision. At a centre level, staff roles varied due to differences in training and health care provision. The annual number of counsellees seen in each participating centre ranged from 200 to over 1,700. Access to breast surveillance or bowel screening varied between countries, again reflecting differences in medical care pathways. These countries converged in regard to the wide availability of professional bodies and published guidelines promoting aspects of service provision. Similarities between centres included provision of a multidisciplinary team, with access to psychological support, albeit with varying degrees of integration. All services were dominated (70–90%) by referrals from families with an increased risk of breast cancer despite wide variation in referral patterns. Collection of pedigree data and risk assessment strategies were broadly similar, and centres used comparable genetic testing protocols. Average consultation times ranged between 45 and 90 min. All centres had access to a laboratory offering DNA testing for breast and bowel cancer-predisposing genes, although testing rates varied, reflecting the stage of service development and the type of population. Israel offered the highest number of genetic tests for breast cancer susceptibility because of the existence of specific founder mutations, in part explaining why the cancer genetics service in Haifa differed most from the other six. Conclusion: Despite considerable differences in service organisation, there were broad similarities in the provision of cancer genetic services in the centres surveyed.

1.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal A, Harshman K, Tavtigian S, Liu QY, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Trant T, McClure M, Frye C, Hattier T, Phelps R, Haugenstrano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;226:66–71.
2.
Wooster R, Neuhausen S, Mangion J, Quirk Y, Ford D, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop D, Spurr N, Ponder B, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir R, Easton D, Bentley D, Futreal P, Ashworth A, Stratton M: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q 12–13. Science 1994;265:2088–2090.
3.
Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, Chadwick RB, Kaariainen H, Eskelinen M, Jarvinen H, Mecklin JP, de la Chapelle A: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481–1487.
4.
Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993;5:1027–1038.
5.
Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A: Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994;368:258–261.
6.
Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T: Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997;7:271–272.
7.
Percesepe A, Borghi F, Menigatti M, Losi L, Di Gregorio C, Rossi G, Pedroni M, Sala E, Vaccina F, Roncucci L, Benatti P, Viel A, Genuardi M, Marra G, Kristo P, Peltomaki P, Ponz de Leon M: Molecular screening for hereditary nonpolyposis colorectal cancer: A prospective, population-based study. J Clin Oncol 2001;19:3944–3950.
8.
Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertson H, Joslyn G, Stevens J, Spirio L, Robertson M, Sargent L, Krapcho K, Wolff E, Burt R, Hughes JP, Warrington J, McPherson J, Wasmuth J, Le Paslier D, Abderrahim H, Cohen D, Leppert M, White R: Identification and characterisation of the familial adenomatous polyposis coli gene. Cell 1991;66:589–600.
9.
Joslyn G, Carlson M, Thliveris A, Albertson H, Gelbert L, Samowitz W, Groden J, Stevens J, Spirio L, Robertson M, Sargent L, Krapcho K, Wolff E, Burt R, Hughes JP, Warrington J, McPherson J, Wasmuth J, Le Paslier D, Abderrahim H, Cohen D, Leppert M, White R: Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 1991;66:601–613.
10.
Kinzler KW, Nilbert MC, Su L-K, Vogelstein B, Bryan TM, Ley DB, Smith KJ, Preisinger C, Hedge P, McKechnie D, Finniear R, Markham A, Groffen J, Boguski MS, Altschul SF, Horii A, Ando H, Miyoshi Y, Miki Y, Nishisho I, Nakamura Y: Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661–665.
11.
Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401–1408.
12.
Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB: The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001;10:467–473.
13.
Evans DGR, Anderson E, Lalloo F, Vasen H, Beckmann M, Eccles D, Hodgson S, Moller P, Chang-Claude J, Morrison P, Stoppa-Lyonnet D, Steel M, Haites N: Utilisation of prophylactic mastectomy in 10 European centres. Dis Markers 1999;15:148–151.
14.
Hodgson S, Milner B, Brown I, Bevilacqua G, Chang-Claude J, Eccles D, Evans G, Gregory H, Moller P, Morrison P, Steel M, Stoppa-Lyonnet D, Vasen H, Haites N: Cancer genetics services in Europe. Dis Markers 1999;15:3–13.
15.
Hofferbert S, Worringen U, Backe J, Ruckert E-M, White K, Faller H, Grimm T, Caffier H, Chang-Claude J, Weber B: Simultaneous interdisciplinary counseling in German breast/ovarian cancer families: First experiences with patient perceptions, surveillance behavior and acceptance of genetic testing. Genet Couns 2000;11:127–146.
16.
Julian-Reynier C, Eisinger F, Chabal, F, Aurran Y, Noguès C, Vennin P, Bignon Y-J, Machelard-Roumagnac M, Maugard-Louboutin C, Serin D, Versini S, Mercuri M, Sobol H: Cancer genetic clinics: Target population and consultees’ expectations. Eur J Cancer 1996;32A:398–403.
17.
Campbell H, Holloway S, Cetnarskyj R, Anderson E, Rush R, Fry A, Gorman D, Steel M, Porteous M: Referrals of women with a family history of breast cancer from primary care to cancer genetics services in South East Scotland. Br J Cancer 2003;89:1650–1656.
18.
Steel M, Smyth E, Vasen H, Eccles D, Evans G, Møller P, Hodgson S, Stoppa-Lyonnet D, Chang-Claude J, Caligo M, Morrison P, Haites N: Ethical, social and economic issues in familial breast cancer: A compilation of views from the E.C. Biomed II Demonstration Project. Dis Markers 1999;15:125–131.
19.
Stopfer JE: Genetic counseling and clinical cancer genetics services. Semin Surg Oncol 2000;18:347–357.
20.
Thompson JA, Wesner GL, Sellers TA, Vachan C, Ahrens M, Potter JD, Sumpmann M, Kersey J: Genetic services for familial cancer patients: A survey of National Cancer Institute Cancer Centres. J Natl Cancer Inst 1995;87:1446–1455.
21.
Vasen HF, Haites NE, Evans DG, Steel CM, Moller P, Hodgson S, Eccles D, Morrison P, Stoppa Lyonet D, Chang-Claude J, Caligo M: Current policies for surveillance and management in women at risk of breast and ovarian cancer: A survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. Eur J Cancer 1998;34:1922–1926.
22.
Wonderling D, Hopwood P, Cull A, Douglas F, Watson M, Burn J, McPherson K: A descriptive study of UK cancer genetics services: An emerging clinical response to the new genetics. Br J Cancer 2001;85:166–170.
23.
Brain K, Gray J, Norman P, France E, Anglim C, Clarke A, Sweetlend H, Tischkowitz M, Myring J, Stansfield K, Webster D, Gower-Thomas K, Daoud R, Gateley C, Monypenny I, Singhal H, Branston L, Sampson J, Roberts E, Newcombe R, Cohen D, Rogers C, Mansel R, Harper P: Randomized trial of a specialist genetic assessment service for familial breast cancer. J Natl Cancer Inst 2000;92:1345–1351.
24.
Fry A, Cull A, Appleton S, Rush R, Holloway S, Gorman D, Cetnarsky R, Thomas R, Campbell J, Anderson E, Steel M, Porteous M, Campbell H: A randomised trial of breast cancer genetics services in South East Scotland: Psychosocial impact. Br J Cancer 2003;89:653–659.
25.
European Commission: Risk communication in cancer genetics: Lay people’s expectations and providers’ practices (CRISCOM); in Martins Bossier A, Kütt W, Joliff-Botrel G (eds): Strategic Accompanying Measures, Catalogue of Contracts (1999–2002). Luxembourg, European Communities, 2003, p 55.
26.
Eisinger F, Alby N, Bremond A, Dauplat J, Espie M, Janiaud P, Kuttenn F, Lebrun JP, Lefranc JP, Pierret J, Sobol H, Stoppa-Lyonnet D, Thouvenin D, Tristant H, Feingold J: Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee. Ann Oncol 1998;9:939–950.
27.
Bundesärztekammer: Richtlinien zur Diagnostik der genetischen Disposition für Krebserkrankungen (German guidelines for the diagnosis of genetic disposition for cancer). Deutsches Ärzteblatt 1998;95:A-1396–A-1403.
28.
Van Asperen CJ, de Bock GH, van der Horst F, de Koning HJ, Rutgers EJ: Screening for breast cancer on basis of individual risk assessment for women ineligible for the national population screening program (in Dutch). Ned Tijdschr Geneeskd 2001;145:120–125.
29.
Sauven P, on behalf of the Association of Breast Surgery Family History Guidelines Panel: Guidelines for the management of women at increased risk of breast cancer. Eur J Cancer 2004;40:653–665.
30.
Eisinger F, Thouvenin D, Bignon YJ, Cuisenier J, Feingold J, Hoerni B, Lasset C, Lyonnet D, Maraninchi D, Marty M, et al: Réflexions sur l’organisation des consultations d’oncogénétique (première étape vers la publication de bonnes pratiques cliniques) [Considerations on the organization of oncologic-genetic consultations (a first step towards the publication of clinical practice guidelines)]. Bull Cancer 1995;82:865–878.
31.
Frebourg T, Abel A, Bonaiti-Pellie C, Brugieres L, Berthet P, Bressac-de Paillerets B, Chevrier A, Chompret A, Cohen-Haguenauer O, Delattre O, Feingold J, Feunteun J, Frappaz D, Fricker JP, Gesta P, Jonveaux P, Kalifa C, Lasset C, Leheup B, Limacher JM, Longy M, Nogues C, Oppenheim D, Sommelet D, Soubrier F, Stoll C, Stoppa-Lyonnet D, Tristant H: Li-Fraumeni syndrome: Update, new data and guidelines for clinical management (in French). Bull Cancer 2001;88:581–587.
32.
Schmutzler R, Schlegelberger B, Meindl A, Gerber W-D, Kiechle M: Beratung, Genetische Testung und Prävention von Frauen mit einer familiären Belastung für das Mamma- und Ovarialkarzinom: Interdisziplinäre Empfehlungen des Verbundprojektes ‘Familiärer Brust- und Eierstockkrebs’ der Deutschen Krebshilfe (Counselling, genetic testing and preventive measures for women with a family history of breast and ovarian cancer: Interdisciplinary recommendations on ‘Familial breast and ovarian cancer’ by the German Cancer Aid joint project). Med Genet 2003;15:385–395.
33.
Leitlinien zur genetischen Beratung. Med Genet 1996;8:1–2. Leitlinien zur molekulargenetischen Labordiagnostik. Med Genet 1996;8:4. (These are guidelines and statements of the German Association of Medical Genetics and the German Society for Human Genetics.)
34.
Bertario L, Aste H, Arrigoni A, Fracasso P, Rossini FP, Rossetti C, Valanzano R: Clinical aspects and management of hereditary non-polyposis colorectal cancer (HNPCC). Tumori 1996;82:117–121.
35.
Trecate G, Vergnaghi D, Bergonzi S, De Simone T, Costa C, Spatti GB, Pasini B, Musumeci R: BMRI in early detection of breast cancer in patients with increased genetic risk: Our preliminary results. J Exp Clin Cancer Res 2002;21(3 suppl):125–130.
36.
Hodgson SV, Bishop DT, Dunlop MG, Evans DG, Northover JM: Suggested screening guidelines for familial colorectal cancer. J Med Screen 1995;2:45–51.
37.
Eccles DM, Evans DG, Mackay J: Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG). J Med Genet 2000;37:203–209.
38.
Van Asperen CJ, Jonker MA, Jacobi CE, van Diemen-Homan JE, Bakker E, Breuning MH, van Houwelingen JC, de Bock GH: Risk estimation for healthy women from breast cancer families: New insights and new strategies. Cancer Epidemiol Biomarkers Prev 2004;13:87–93.
39.
Claus EB, Risch N, Thomson WD: Autosomal dominant inheritance of early onset breast cancer. Cancer 1994;73:643–651.
40.
Berry MO, Parmigiani G, Sanchez J, Schildkraut J, Winer E: Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997;89:227–238.
41.
Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2:Analysis of 10,000 individuals. J Clin Oncol 2002;20:1480–1490.
42.
Rodriguez-Bigas M, Boland R, Hamilton SR, Henson DE, Jass JR, Meera Khan P, Lynch H, Perucho M, Smyrk T, Sobin L, Srivastava S: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: Meeting highlights and Bethesda Guidelines. J Natl Cancer Inst 1997;89:1758–1762.
43.
Evans DGR, Bulman M, Young K, Gokhale D, Lalloo F: Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families. J Med Genet 2003;40:e107.
44.
Hendriks Y, Franken P, Dierssen JW, De Leeuw W, Wijnen J, Dreef E, Tops C, Breuning M, Brocker-Vriends A, Vasen H, Fodde R, Morreau H: Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol 2003;162:469–477.
45.
Leach FS, Polyak K, Burrell M, Johnson KA, Hill D, Dunlop MG, Wyllie AH, Peltomaki P, de la Chapelle A, Hamilton SR, Kinzler KW, Vogelstein B: Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Cancer Res 1996;56:235–240.
46.
Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM, Moslein G, Baker SM, Liskay RM, Burgart LJ, Honchel R, Halling KC: Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 1996;56:4836–4840.
47.
Sevilla C, Moatti JP, Julian-Reynier C, Eisinger F, Stoppa-Lyonet D, Bressac de Paillerets B, Sobol H: Testing for BRCA1 mutations: A cost-effectiveness analysis. Eur J Hum Genet 2002;10:599–606.
48.
Knorr C, Karin D: The Manufacture of Knowledge: An Essay on the Constructivist and Contextual Nature of Science. Oxford, Pergamon, 1981.
49.
Knorr-Cetina KD: The culture of knowledge societies; in Epistemic Cultures: How the Sciences Make Knowledge, chap 1.2. Cambridge, MA, Harvard University Press, 1999.
50.
Ash A, Cohendet P: Architectures of Knowledge. Firms, Capabilities and Communities. Oxford, Oxford University, in press.
51.
Evans DG, Blair V, Greenhalgh R, Hopwood P, Howell A: The impact of genetic counselling on risk perception in women with a family history of breast cancer. Br J Cancer 1994;70:934–938.
52.
McPherson K: Variations entre pays des pratiques médicales; in: Les systèmes de santé à la recherche d’efficacité. Paris, OCDE, 1990, pp 17–30.
53.
Payer L: Medicine and Culture: Varieties of Treatment in the United States, England, West Germany and France. London, Penguin, 1988.
54.
McIntosh A, Shaw C, Evans G, Turnbull N, Bahar N, Barclay M, Easton D, Emery J, Gray J, Halpin J, Hopwood P, KcKay J, Sheppard C, Sibbering M, Watson W, Wailoo A, Hutchinson A: Clinical Guidelines and Evidence Review for the Classification and Care of Women at Risk of Familial Breast Cancer. London, National Collaborating Centre for Primary Care/University of Sheffield, 2004.
55.
National Institute for Clinical Excellence: Clinical Guidelines for the Classification and Care of Women at Risk of Familial Breast Cancer (Clinical Guideline 14). Developed by National Collaborating Centre for Primary Care/ University of Sheffield. National Institute for Clinical Excellence, London, May 2004 (www.nice.org.uk).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.